Stephen C. Knight, MD, Chairman
President, Fidelity Biosciences
Biography: Dr. Knight currently serves as Chairman of the Board of Directors for FORUM Pharmaceuticals. He joined Fidelity BioSciences, a healthcare venture firm owned by Fidelity, in 2003 as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for more than 20 years. Prior to joining Fidelity, Dr. Knight was President and Chief Operating Officer for EPIX Pharmaceuticals in Cambridge, Massachusetts. Before joining EPIX, Dr. Knight worked at Arthur D. Little Inc., specializing in mergers and acquisitions in the pharmaceutical industry, and performed research at AT&T Bell Laboratories, the National Institutes of Health, and Yale University.
Dr. Knight serves on the Board of Directors of Innovent Biologics, Inc., Proteostasis Therapeutics, Iora Health, Blueprint Medicines, Pulmocide, and Optegra Global Ltd. Dr. Knight previously served on the boards of several private and public healthcare companies including FoldRx (acquired by Pfizer) Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), and Respivert, Ltd. (acquired by J&J).
Education: Dr. Knight holds an MD from the Yale University School of Medicine and an MBA from the Yale School of Organization and Management. Dr. Knight also earned a BS in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.